AMARILLO, TX--(MARKET WIRE)--Aug 2, 2007 -- Amarillo Biosciences, Inc. (ABI) (OTC BB:AMAR.OB - News) today announced that it has agreed to conduct human influenza research with Dr. Manfred Beilharz, Chair of Microbiology and Immunology, School of Biomedical, Bimolecular and Chemical Sciences, The University of Western Australia. “We have been collaborating with Dr. Beilharz for more than 10 years,” said Dr. Cummins, CEO of ABI. “During that time, Dr. Beilharz has published 10 scientific papers or abstracts on the low-dose, oral use of interferon. We are pleased to extend our research collaboration with Dr. Beilharz. His exciting discoveries regarding how oral interferon can protect against influenza are critically important as the world prepares for the next influenza pandemic,” said Dr. Joseph Cummins.
